AOP-Wiki

API

All KERs

Showing 1576 to 1600 of 3129 KERs

ID	Upstream Event	Downstream Event	Creation Date	Last Updated	AOPs

2226	1827: Increase, Global methylation	1365: Increase, Apoptosis	Dec 4, 2020	Dec 4, 2020	None
385	122: Increase, GR activation	145: Induction, IKB inhibitory protein	Nov 29, 2016	Dec 3, 2016	1 AOP 14: Glucocorticoid Receptor Activation Leading to Increased Disease Susceptibility
1451	122: Increase, GR activation	1335: Reduced, BDNF	Apr 14, 2017	Apr 14, 2017	1 AOP 214: Network of SSRIs (selective serotonin reuptake inhibitors)
2039	122: Increase, GR activation	860: Decreased, Mitochondrial Fatty Acid Beta Oxidation	Feb 22, 2020	Feb 22, 2020	None
2041	122: Increase, GR activation	231: Decreased, PPAR-alpha activation	Feb 22, 2020	Feb 22, 2020	None
2261	122: Increase, GR activation	54: Up Regulation, CD36	Jan 15, 2021	Jan 15, 2021	None
2266	122: Increase, GR activation	1834: Decrease, ACAD	Jan 15, 2021	Jan 15, 2021	1 AOP 318: Glucocorticoid Receptor activation leading to hepatic steatosis
3526	122: Increase, GR activation	2245: Altered cell differentiation signaling	Apr 18, 2025	Apr 18, 2025	1 AOP 334: Glucocorticoid Receptor Agonism Leading to Impaired Fin Regeneration
3738	122: Increase, GR activation	2119: Increase, Insulin resistance	Feb 12, 2026	Feb 12, 2026	3 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress
3739	122: Increase, GR activation	450: Decrease, VLDL export capacity	Feb 12, 2026	Feb 12, 2026	None
3740	122: Increase, GR activation	1306: Increase, De novo lipogenesis	Feb 12, 2026	Feb 12, 2026	3 AOPs 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
2885	2133: Increase, Glucuronidation of T4	961: Increased, Clearance of thyroxine from serum	Apr 12, 2023	Apr 12, 2023	None
2794	2070: Increase, Glycolysis	2071: Decrease, Glucose pool	Nov 1, 2022	Nov 1, 2022	1 AOP 267: Uncoupling of oxidative phosphorylation leading to growth inhibition via glucose depletion
2858	2117: Increase, goblet cell number	962: Increase, Mucin production	Mar 15, 2023	Mar 17, 2023	1 AOP 148: EGFR Activation Leading to Decreased Lung Function
3212	2137: Increase, Gonadotropins concentration in plasma	1690: Decrease, circulating testosterone levels	May 8, 2024	May 8, 2024	None
3716	2137: Increase, Gonadotropins concentration in plasma	2402: Increased, E2 production in ovaries	Jan 29, 2026	Feb 3, 2026	4 AOPs 623: Activation, estrogen receptor alpha leads to persistent vaginal cornification via increased kisspeptin release 637: Activation, estrogen receptor alpha leads to increased uterine weight via earlier proliferation of cells of the uterine lining 639: Activation, estrogen receptor alpha leads to precocious puberty via increased kisspeptin release 640: Activation, estrogen receptor alpha leads to decreased fertility via prolonged estrus cycle
3679	2383: Increase, Hemopericardium	947: Increase, Early Life Stage Mortality	Oct 30, 2025	Oct 30, 2025	3 AOPs 612: Peroxisome proliferator-activated receptor alpha activation leading to early life stage mortality via reduced adenosine triphosphate 613: Peroxisome proliferator-activated receptor alpha activation leading to early life stage mortality via increased reactive oxygen species production 614: Peroxisome proliferator-activated receptor alpha activation leading to early life stage mortality via reduced vascular endothelial growth factor
3742	2412: Increase, Hepatic intracellular active GC	122: Increase, GR activation	Feb 24, 2026	Feb 24, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
295	265: Increase, HSC activation	68: Increase, Collagen accumulation	Nov 29, 2016	Dec 5, 2018	8 AOPs 38: Protein Alkylation leading to Liver Fibrosis 144: Endocytic lysosomal uptake leading to liver fibrosis 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
2892	265: Increase, HSC activation	1501: Increase, ECM deposition	Apr 13, 2023	Jan 30, 2025	1 AOP 494: AhR activation leading to liver fibrosis
3217	265: Increase, HSC activation	459: Increase, Liver steatosis	May 14, 2024	May 14, 2024	None
3725	2405: Increase, Hepatocellular lipotoxicity	177: Increase, Mitochondrial dysfunction	Feb 10, 2026	Feb 10, 2026	1 AOP 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction
3736	2405: Increase, Hepatocellular lipotoxicity	1815: Increase, ER stress	Feb 11, 2026	Feb 11, 2026	2 AOPs 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
3745	2405: Increase, Hepatocellular lipotoxicity	1392: Increase, Oxidative Stress	Feb 24, 2026	Feb 24, 2026	2 AOPs 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress
1994	1698: Increase, hypermethylation of the promotor region of GnRHR	1699: Decease, expression of GnRHR	Oct 30, 2019	Oct 30, 2019	1 AOP 310: Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR

Key Event Relationships (KERs)

All KERs